Hospitalization

Also known as: Hospitalisation / Hospitalization NOS / Inpatient care

DrugDrug NameDrug Description
DB01076AtorvastatinAtorvastatin is a member of the statins firstly synthesized in 1985 by Dr. Bruce Roth and FDA approved in 1996.[T568] It is a pentasubstituted pyrrole[A177415] formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound.[T571] Unlike other members of the statin group, atorvastatin is an active compound and hence, it does not require activation.[A177436] It is the most widely used and potent member of the statin group.[T568]
DB12364BetrixabanBetrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [A7708]. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [A27286]. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE [A27285]. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [A27287].
DB00177ValsartanValsartan is an angiotensin-receptor blocker (ARB) that may be used to manage hypertension and heart failure. Many studies have demonstrated the efficacy of valsartan in reducing blood pressure (BP) in many patient populations (including elderly, women, children, obese patients, patients with diabetes mellitus, patients with chronic kidney disease (CKD), patients at high risk of cardiovascular (CV) disease, African Americans, Hispanic Americans and Asians) and in improving the clinical outcome in cardiovascular (CV) disease and chronic kidney disease (CKD) [A174124]. Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States [A174124]. This drug is generally well-tolerated with a side-effect profile superior to that of other antihypertensive drugs [A174130], [A174133].
DrugDrug NameTargetType
DB01076Atorvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB01076AtorvastatinCytochrome P450 3A4enzyme
DB01076AtorvastatinDipeptidyl peptidase 4target
DB01076AtorvastatinCytochrome P450 2D6enzyme
DB01076AtorvastatinCytochrome P450 2C9enzyme
DB01076AtorvastatinCytochrome P450 2C19enzyme
DB01076AtorvastatinCytochrome P450 3A5enzyme
DB01076AtorvastatinCytochrome P450 3A7enzyme
DB01076AtorvastatinMultidrug resistance protein 1transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1A2transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1B1transporter
DB01076AtorvastatinMultidrug resistance-associated protein 4transporter
DB01076AtorvastatinMultidrug resistance-associated protein 5transporter
DB01076AtorvastatinMultidrug resistance-associated protein 1transporter
DB01076AtorvastatinCytochrome P450 2B6enzyme
DB01076AtorvastatinCytochrome P450 2C8enzyme
DB01076AtorvastatinAryl hydrocarbon receptortarget
DB01076AtorvastatinSolute carrier organic anion transporter family member 2B1transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1B3transporter
DB01076AtorvastatinUDP-glucuronosyltransferase 1-1enzyme
DB01076AtorvastatinUDP-glucuronosyltransferase 1-3enzyme
DB01076AtorvastatinCanalicular multispecific organic anion transporter 1transporter
DB01076AtorvastatinBile salt export pumptransporter
DB01076AtorvastatinSerum albumincarrier
DB12364BetrixabanMultidrug resistance protein 1transporter
DB12364BetrixabanCoagulation factor Xtarget
DB12364BetrixabanPotassium voltage-gated channel subfamily H member 2transporter
DB12364BetrixabanProthrombinenzyme
DB00177ValsartanType-1 angiotensin II receptortarget
DB00177ValsartanCytochrome P450 2C9enzyme
DB00177ValsartanSolute carrier organic anion transporter family member 1B3transporter
DB00177ValsartanSolute carrier organic anion transporter family member 1B1transporter
DB00177ValsartanCanalicular multispecific organic anion transporter 1transporter
DrugDrug NamePhaseStatusCount
DB01593Zinc1Completed1
DB12768BCG vaccine4Recruiting1
DB00878Chlorhexidine4Recruiting1
DB00046Insulin Lispro4Completed1
DB00047Insulin glargine4Completed1
DB02325Isopropyl alcohol4Recruiting1
DB06812Povidone-iodine4Recruiting1
DB01261Sitagliptin4Completed1
DB09153Sodium chloride4Recruiting1
DB01593ZincNot AvailableCompleted1